Centessa Pharmaceuticals plc — Director's Dealing 2025

Apr 22, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2025-04-21

Reporting Person: SAHA SAURABH (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-04-21	Ordinary Shares	S	14656	$12.2885	Disposed	261361	Direct
2025-04-22	Ordinary Shares	S	40344	$12.43	Disposed	221017	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	38000	Indirect

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2024.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.23 to $12.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: These shares are held directly in a trust, for which the Reporting Person and his spouse serve as trustees.